[ad_1]
GlaxoSmithKline plc (NYSE: GSK) was awarded an average rating of "Hold" from the seventeen research companies that cover the stock, Marketbeat reports. Three badysts have rated the stock with a sales note, eight have badigned a credit rating and five have awarded a purchase grade to the company, an average price target of 12 months for badysts who have changed their coverage from last year.
Several research firms recently published reports on GSK Zacks Investment Research lowered GlaxoSmithKline shares from a "hold" note to a "sell" note in a research report on Thursday, June 14, 2009 Deutsche Bank reaffirmed a "neutral" rating on GlaxoSmithKline shares in a report on Monday, April 9, 2004. BNP Paribas upgraded GlaxoSmithKline's shares from a "neutral" rating to a "outperforming" rating in a report from Wednesday, April 4th. posted shares of GlaxoSmithKline from an "underweight" rating to an "equal weight" rating in a report on Thursday, March 22. Finally, DZ Bank confirmed the note "purchase" on the shares of GlaxoSmithKline in a statement on Thursday, June 14.
In addition, the majority shareholder Plc Glaxosmithkline acquired 269,230 shares in a transaction dated Monday, July 2. The stock was purchased at an average price of $ 13.00 per share, for a total value of $ 3,499,990.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The insiders of the company own 10.00% of the shares of the company.
Several institutional investors and hedge funds recently added or reduced their holdings in GSK. We Are One Seven LLC increased its stake in GlaxoSmithKline shares by 185.1% in the first quarter. We Are One Seven now owns 2,677 shares of the pharmaceutical company valued at $ 105,000 following the purchase of 1,738 additional shares during the last quarter. Adviser Investments LLC purchased a new equity interest in GlaxoSmithKline during the first quarter, valued at approximately $ 117,000. The Toronto Dominion Bank increased its holdings in GlaxoSmithKline by 133.3% in the first quarter. The Toronto Dominion Bank now holds 3,150 shares of the pharmaceutical company valued at $ 123,000 after purchasing 1,800 additional shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new equity interest in GlaxoSmithKline shares during the first quarter, valued at approximately $ 135,000. Lastly, Wealthcare Advisory Partners LLC increased its stake in GlaxoSmithKline shares by 80.8% in the first quarter. Wealthcare Advisory Partners LLC now holds 3,570 shares of the pharmaceutical company valued at $ 139,000 after purchasing 1,595 additional shares in the last quarter. 11.07% of the shares are currently held by institutional investors and hedge funds.
GlaxoSmithKline grew $ 0.29 to $ 41.02 during Friday's trading day, according to Marketbeat reports. The company's stock had a trading volume of 1,865,600 shares, compared to its average volume of 3,308,710. GlaxoSmithKline has a low of fifty-two weeks of $ 34.52 and a high of $ 52.94. The company has a ratio of 0.40, a liquidity ratio of 0.61 and a debt ratio of 3.90. The company has a market capitalization of $ 100.79 billion, a PE ratio of 14.17, a price / earnings ratio of 2.33 and a beta of 0.82.
GlaxoSmithKline (NYSE: GSK) last published its quarterly results on Wednesday, April 25. The pharmaceutical company reported earnings per share (EPS) of $ 0.68 for the quarter, with the exception of Thomson Reuters' estimated consensus of $ 0.70 ($ 0.02). GlaxoSmithKline had a return on equity of 144.84% and a net margin of 3.50%. The company achieved a turnover of $ 10.04 billion during the quarter, compared with $ 10.26 billion for badysts. Research badysts expect GlaxoSmithKline to publish 2.79 EPS for the current year.
The company also recently unveiled a quarterly dividend that will be paid on Thursday, July 12. Shareholders of record on Friday, May 11 will receive a dividend of $ 0.5298 per share. This represents an annualized dividend of $ 2.12 and a dividend yield of 5.17%. The ex-dividend date of this dividend is Thursday, May 10. The distribution rate of GlaxoSmithKline is 72.92%.
Company Profile GlaxoSmithKline
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture and marketing of vaccines, over-the-counter medications and consumer products related to health. It operates through four segments: Pharmaceuticals, Pharmaceutical R & D, Vaccines and Consumer Healthcare. The company offers pharmaceutical products including drugs in the therapeutic areas, such as respiratory tract, antiviral, central nervous system, cardiovascular and urobad, metabolic, antibacterial, dermatological, rare diseases, immuno-inflammation and the HIV, along with Vaccines
Receive News and Reviews for GlaxoSmithKline Daily – Enter your email address below to receive a concise daily summary of the latest news and badyst ratings for GlaxoSmithKline and related companies with the FREE Daily E-newsletter from MarketBeat.com.
Source link
